LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

Начало・Списък с акции・Johnson and Johnson

Johnson and Johnson

Затворен

Сектор Здравеопазване

164.37 -0.29

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

164.14

Максимум

164.71

Ключови измерители
By Trading Economics
Приходи	1.4B 4.7B
Продажби	1.1B 22B
P/E Средно за сектора	21.72 103.001
EPS	2.82
Марж на печалбата	20.873
Служители	131,900
EBITDA	2.1B 7.8B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+4.92 upside

Дивиденти
By Dow Jones
Следващи печалби	15.10.2024 г.
Следваща дата на дивидент	10.09.2024 г.
Следваща дата на екс-дивидент	18.11.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	400B
Предишно отваряне	164.66
Предишно затваряне	164.37

Настроения в новините

By Acuity

41%

59%

90 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

164.13 / 164.61 Подкрепа & съпротива

Johnson and Johnson Графика

Свързани новини

20.08.2024 г., 12:16 ч. UTC

Придобивния, сливания и поглъщания

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600 Million

20.08.2024 г., 11:43 ч. UTC

Топ новини

Johnson & Johnson's Rybrevant, Lazcluze Combo Gets FDA Approval for Type of Advanced Lung Cancer

17.07.2024 г., 14:14 ч. UTC

Печалби

Trending: Johnson & Johnson Beats 2Q Sales Guidance

4.09.2024 г., 23:20 ч. UTC

Топ новини

Johnson & Johnson Wins Over Longtime Holdout for Talc Settlement -- Update

23.08.2024 г., 20:54 ч. UTC

Топ новини

J&J Takes Aim at Hospital Drug-Discount Program -- Update

23.08.2024 г., 18:09 ч. UTC

Топ новини

J&J Takes Aim At Hospital Drug-Discount Program -- WSJ

20.08.2024 г., 12:41 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Johnson & Johnson Gets FDA Approval for Treatment, Makes Acquisition of Up to $1.7 Billion -- Barrons.com

20.08.2024 г., 12:01 ч. UTC

Придобивния, сливания и поглъщания

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600M

20.08.2024 г., 11:55 ч. UTC

Придобивния, сливания и поглъщания

J&J To Acquire V-Wave For Up To $1.7 Billion In Play For Heart Failure Device -- MarketWatch

20.08.2024 г., 11:31 ч. UTC

Придобивния, сливания и поглъщания

Johnson & Johnson Expects the Transaction to Dilute Adjusted EPS by 24c in 2024 and 6c in 2025 >JNJ

20.08.2024 г., 11:31 ч. UTC

Придобивния, сливания и поглъщания

Johnson & Johnson Transaction Is Expected to Close Before the End of 2024 >JNJ

20.08.2024 г., 11:31 ч. UTC

Придобивния, сливания и поглъщания

Johnson & Johnson Will Join Johnson & Johnson as Part of Johnson & Johnson MedTech >JNJ

20.08.2024 г., 11:31 ч. UTC

Придобивния, сливания и поглъщания

Johnson & Johnson Will Acquire V-Wave for an Upfront Payment of $600M With the Potential for Additional Regulatory and Comml Milestone Payments Up to $1.1B >JNJ

20.08.2024 г., 11:30 ч. UTC

Придобивния, сливания и поглъщания

Johnson & Johnson To Acquire V-Wave >JNJ

20.08.2024 г., 11:12 ч. UTC

Топ новини

Johnson & Johnson Wins First FDA Approval For Chemotherapy-Free Lung Cancer Treatment -- MarketWatch

12.08.2024 г., 14:30 ч. UTC

Придобивния, сливания и поглъщания

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12.08.2024 г., 09:30 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Big Drugmakers Are Clinching Smaller Deals -- WSJ

29.07.2024 г., 10:30 ч. UTC

Топ новини

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

17.07.2024 г., 11:24 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

J&J Lifts Sales View But Lowers Earnings Outlook -- Market Talk

17.07.2024 г., 10:43 ч. UTC

Печалби

Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered Guidance -- IBD

17.07.2024 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: MedTech Operational Sales Growth Expected to Accelerate in 2H >JNJ

17.07.2024 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Cuts 2024 View To Adj EPS $9.97-Adj EPS $10.07 Vs Prior View $10.57-$10.72 >JNJ

17.07.2024 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Backs 2024 Adjusted Operational Sales Growth View of 5.5%-6% >JNJ

17.07.2024 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: 2Q MedTech Worldwide Operational Sales Growth Was Driven Primarily by Electrophysiology Products and Abiomed in Cardiovascular, and Wound Closure Products in General Surgery >JNJ

17.07.2024 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Backs 2024 Sales $88.0B-$88.4B >JNJ

17.07.2024 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $10.00-$10.10 Vs Prior View $10.60-$10.75 >JNJ

17.07.2024 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: 2Q Innovative Medicine Worldwide Operational Sales, Excluding Covid Vaccine, Grew 8.8% >JNJ

17.07.2024 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Updating 2024 Guidance to Reflect Improved Performance and Impact for Recent Acquisitions of Shockwave Medical, Proteologix and NM26 Bispecific Antibody >JNJ

17.07.2024 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Raises 2024 Operational Sales View to $89.2B-$89.6B Vs Prior View $88.7B-$89.1B >JNJ

17.07.2024 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 2Q Worldwide MedTech Sales $7.96B >JNJ

Сравнение с други в отрасъла

Ценова промяна

Johnson and Johnson Прогноза

Ценова цел

By TipRanks

4.92% нагоре

12-месечна прогноза

Среден 172.46 USD 4.92%

Висок 215 USD

Нисък 150 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Johnson and Johnson през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Johnson and Johnson през последните 3 месеца.

Техническа оценка

By Trading Central

164.13 / 164.61Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

90 / 365 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.